drugset / Trial / NCT02551861
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if 8 weeks of Daclatasvir plus Sofosbuvir with or without Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients without advanced fibrosis or liver cirrhosis who have never been treated previously.
Timeline
- Start
- 2015-12
- Primary completion
- 2016-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclatasvir | Small molecule | 60 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1000 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1200 mg | Oral |
| Comparator | Sofosbuvir | Small molecule | 400 mg | Oral |